Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 2, 2011

View Archived Issues

Phase I study of JVS-100 complete

First-in-human results presented on PRS-050 in patients with advanced solid malignancies

Costimulatory fusion protein enhances activity of tumor vaccine in vivo

Takeda presents new antiatherosclerotic compounds

Preclinical study assesses antitumor effects of Pfizer's new antibody-drug conjugate

Medunik Canada acquires Canadian rights to two orphan therapies from QOL Medical

Idera Pharmaceuticals obtains FDA authorization for IMO-3100 trial

Anthera Pharmaceuticals completes interim analysis of PEARL-SC study

Novel PI3K and mTOR inhibitors patented by Spanish researchers

XTL Biopharmaceuticals acquires MinoGuard

New apoptosis inhibitors described in Chinese PLA General Hospital patent

Evotec patents novel orexin OX2 receptor antagonists

New beta-secretase inhibitors discovered by Roche and Siena Biotech

Octagam 5% now available again in the U.S.

Novel caspase-3 activators and apoptosis inducers reported in patent literature

NovaBay advances phase II NVC-422 study

FDA grants orphan drug designation to Emergent's TRU-016

Curis and the Leukemia and Lymphoma Society agree to develop CUDC-907

Ceregene completes enrollment in second phase II CERE-120 study

Auxilium Pharmaceuticals doses first patient in Xiaflex study

Brewer Sports International to fund traumatic brain injury research

MacroGenics and Servier enter into license agreement for MGA-271

Celldex Therapeutics begins phase III trial of rindopepimut

Generex provides update on clinical and regulatory status of buccal insulin spray

NPS Pharmaceuticals files NDA seeking FDA approval of Gattex

EMA approves combination antimalarial drug Eurartesim

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...